|Bid||6.60 x 900|
|Ask||6.85 x 2900|
|Day's Range||6.83 - 7.11|
|52 Week Range||2.71 - 7.56|
|Beta (5Y Monthly)||1.29|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 04, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||9.13|
We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is...
Cerus Corporation (Nasdaq:CERS) announced today that INTERCEPT Blood Systems disposable kit shipments have surpassed 7.5 million treatable platelet and plasma doses globally since commercial launch.
Ladies and gentlemen, thank you for standing by, and welcome to the CERUS Corp. Q2 2020 Earnings Conference Call. With me on the call are Obi Greenman, Cerus' President and Chief Executive Officer; Dr. Nina Mufti, Cerus' Vice President, Development and Red Blood Cell Program leader; Kevin Green, Cerus' Chief Financial Officer; Vivek Jayaraman, Cerus' Chief Operating Officer; Dr. Laurence Corash, Cerus' Chief Scientific Officer; and Carol Moore, our Senior Vice President of Regulatory Affairs and Quality.